Showing results (81-90 of 105) with videos related to
Sort By:
Pageof 11
Haematologica|January 29, 2008
High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphomaSilvia Montoto, Carol Moreno, Eva Domingo-Doménech, et al.Cancer Medicine|May 1, 2021
Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphomaGloria Iacoboni, Guillermo Villacampa, Nuria Martinez-Cibrian, et al.Blood|June 15, 2011
Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironmentAsh A Alizadeh, Andrew J Gentles, Alvaro J Alencar, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|November 13, 2024
Optimizing CAR-T treatment: A T2EVOLVE guide to raw and starting material selectionSergio Navarro, Carole Moukheiber, Susana Inogés Sancho, et al.Haematologica|May 30, 2013
MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapyAlexandra Valera, Armando López-Guillermo, Teresa Cardesa-Salzmann, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2009
Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometrySandra Quijano, Antonio López, Juan Manuel Sancho, et al.Acta Haematologica|May 19, 2016
Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly PatientsEva González-Barca, Miguel A Canales, Antonio Salar, et al.Cell|September 4, 2010
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphomaMark P Chao, Ash A Alizadeh, Chad Tang, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 3, 2025
Implementation of the precision oncology program in catalonia's public health system: results, lessons learned, and future prospectsPilar Mur, Anna Pozuelo, Josep Tabernero, et al.Blood|January 22, 2025
HSP-CAR30 with a high proportion of less-differentiated T cells promotes durable responses in refractory CD30+ lymphomaAna Carolina Caballero, Cristina Ujaldón-Miró, Paula Pujol-Fernández, et al.Pageof 11